

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

NCT06686524

Status	RECRUITING
Phase	Phase 1
Sponsor	Chongqing Precision Biotech Co., Ltd
Enrollment	18 participants

Key Eligibility Criteria

Inclusion (16)

- (1) Age ≥ 5 years old;
- (2) Diagnosis of juvenile dermatomyositis (JDM) according to Bohan and Peter criteria;
- (3) Meeting the classification criteria for RJDM, and meeting condition 1 and any one of the following conditions:
 - Intolerance or inadequate response to glucocorticoids (prednisone 1-2mg/kg/d or equivalent dose of other hormones) and at least two immunosuppressants, with hormone therapy lasting for at least 6 months;
 - Rapid progression of the disease and/or involvement of organs such as lungs, heart, and gastrointestinal tract;
- ... and 11 more (see full listing online)

Exclusion (13)

- Subjects meeting any of the following criteria will be excluded from this trial:
 - (1) Previously received CAR-T cell therapy (except for those whose safety risks have been judged as eliminated by the investigator);
 - (2) Accompanied by primary immunodeficiency disease or severe secondary immunodeficiency disease that has not been corrected;
 - (3) Accompanied by severe, active, or uncontrolled infectious diseases, including but not limited to active tuberculosis, latent tuberculous infection, active viral hepatitis, etc.;
 - (4) Known to have active malignant diseases or confirmed malignancies before screening (including hematological malignancies and solid tumors, except for resected and cured cutaneous basal cell carcinoma);
- ... and 8 more (see full listing online)

Locations (1 total)

Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, Hangzhou, Zhejiang, China